1. Home
  2. EVLV vs ABUS Comparison

EVLV vs ABUS Comparison

Compare EVLV & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVLV
  • ABUS
  • Stock Information
  • Founded
  • EVLV 2013
  • ABUS 2005
  • Country
  • EVLV United States
  • ABUS United States
  • Employees
  • EVLV N/A
  • ABUS N/A
  • Industry
  • EVLV Computer peripheral equipment
  • ABUS Biotechnology: Pharmaceutical Preparations
  • Sector
  • EVLV Technology
  • ABUS Health Care
  • Exchange
  • EVLV Nasdaq
  • ABUS Nasdaq
  • Market Cap
  • EVLV 671.9M
  • ABUS 685.7M
  • IPO Year
  • EVLV N/A
  • ABUS N/A
  • Fundamental
  • Price
  • EVLV $6.07
  • ABUS $3.21
  • Analyst Decision
  • EVLV Buy
  • ABUS Strong Buy
  • Analyst Count
  • EVLV 2
  • ABUS 4
  • Target Price
  • EVLV $6.50
  • ABUS $5.50
  • AVG Volume (30 Days)
  • EVLV 2.9M
  • ABUS 793.1K
  • Earning Date
  • EVLV 08-07-2025
  • ABUS 07-31-2025
  • Dividend Yield
  • EVLV N/A
  • ABUS N/A
  • EPS Growth
  • EVLV N/A
  • ABUS N/A
  • EPS
  • EVLV N/A
  • ABUS N/A
  • Revenue
  • EVLV $113,691,000.00
  • ABUS $6,403,000.00
  • Revenue This Year
  • EVLV $25.98
  • ABUS $3.35
  • Revenue Next Year
  • EVLV $19.21
  • ABUS N/A
  • P/E Ratio
  • EVLV N/A
  • ABUS N/A
  • Revenue Growth
  • EVLV 36.70
  • ABUS N/A
  • 52 Week Low
  • EVLV $2.04
  • ABUS $2.71
  • 52 Week High
  • EVLV $6.45
  • ABUS $4.73
  • Technical
  • Relative Strength Index (RSI)
  • EVLV 65.36
  • ABUS 32.83
  • Support Level
  • EVLV $6.01
  • ABUS $3.04
  • Resistance Level
  • EVLV $6.45
  • ABUS $3.65
  • Average True Range (ATR)
  • EVLV 0.28
  • ABUS 0.13
  • MACD
  • EVLV 0.03
  • ABUS -0.05
  • Stochastic Oscillator
  • EVLV 80.28
  • ABUS 8.20

About EVLV Evolv Technologies Holdings Inc.

Evolv Technologies Holdings Inc offers an AI-based touchless security screening. Its touchless security screening systems use artificial intelligence software, cloud services, and sensors to reliably detect dangerous weapons while ignoring harmless items like cell phones, laptops, and keys. It offers products for purchase under a multi-year security-as-a-service subscription pricing model that delivers ongoing value to customers, generates predictable revenue, and creates expansion and upsell opportunities. The firm operates in a single segment that develops, manufactures, markets, and sells security screening products and specific services. Its products are used in different industries such as casinos, industrial workplaces, schools, and ticketed venues.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: